|Bid||8.29 x 3000|
|Ask||8.39 x 900|
|Day's range||8.13 - 8.88|
|52-week range||3.50 - 24.90|
|Beta (5Y monthly)||0.39|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2021 - 09 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||13.40|
Shares of Vaxart (Nasdaq: VXRT) rose on Monday after the biotech said the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for its oral coronavirus vaccine. As of 2:20 p.m. EDT, Vaxart's stock price was up more than 12%. Vaxart's S-only vaccine construct produced higher serum antibodies than its other vaccine candidate, which expresses both S and N proteins, in a non-human primate study.
Coronavirus vaccine stocks were the biggest investment theme of 2020. Since, two biotech companies -- Moderna (NASDAQ: MRNA) and BioNTech -- actually have commercialized their vaccines. Let's take a look at where they're at with vaccine programs -- and whether they're on track to beat the market in the second half.
VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.